Tolerizing Mice to Human Leukocytes: A Step Toward the Production of Monoclonal Antibodies Specific for Human Dendritic Cells
Part of the
Advances in Experimental Medicine and Biology
book series (AEMB, volume 329)
Despite several attempts to isolate a mAb specific for human dendritic cells, none currently exists. Recent attempts have utilized an improved dendritic cell purification method to prepare immunogens1 and a rapid two-color flow cytometric screening procedure that allows large numbers of hybridoma supernatants to be examined in each fusion2. Yet these improvements have also failed, yielding only hybridomas that bind “shared” antigens expressed by both dendritic cells and other leukocytes. Dendritic cells express many shared antigens, including CD45 [leukocyte common antigen], CD40, leukocyte [β2] integrins CD11a and CD11c, CD54 [ICAM-1], CD44 [Pgp-1], CD58 [LFA-3], and the B7/BB1 antigen. Therefore, we are attempting to bias the immune response toward rarer, dendritic cell-specific clones by tolerizing or immunosuppressing our animals to shared antigens.
In one approach, adult mice held in barrier cages are injected with “nondendritic” cells and cyclophosphamide [CP], in order to ablate responding “nonspecific” B cell clones. Fifteen days after the last dose of CP, they are challenged with nondendritic cells. A week later they are bled, and serum antibody titers against nondendritic cells are determined by FACS, in order to demonstrate tolerance compared to controls injected with CP alone.
In the second approach, neonatal mice are injected with human T lymphoblasts at birth, followed by boosting at 1 week. In adulthood, they are challenged sequentially with sheep erythrocytes [sRBC], then with T blasts, to demonstrate that they can respond to unrelated cells but not to tolerogenic cells. One week after each kind of challenge, mice are bled and serum antibody levels are determined for treated and sham-injected mice.
When these two approaches were compared, CP led only to nonspecific immunosuppression, while neonatal injections produced selective, antigen-specific nonresponsiveness to the tolerizing T blasts.
KeywordsDendritic Cell Sheep Erythrocyte Human Dendritic Cell Serum Antibody Level Shared Antigen
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
P. S. Freudenthal and R. M. Steinman, The distinct surface of human blood dendritic cells, as observed after an improved isolation method, Proc. Natl. Acad. Sci. USA
87: 7698 (1990).PubMedCrossRefGoogle Scholar
J. P. Metlay, M. D. Witmer-Pack, R. Agger, M. T. Crowley, D. Lawless, and R. M. Steinman, The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies, J. Exp. Med.
171: 1753 (1990).PubMedCrossRefGoogle Scholar
W. D. Matthew and P. H. Patterson, The production of a monoclonal antibody that blocks the action of a neurite outgrowth-promoting factor, Cold Spring Harbor Symp. Quant. Biol.
48: 625 (1983).PubMedCrossRefGoogle Scholar
S. Hockfield, A mAb to a unique cerebellar neuron generated by immunosuppression and rapid immunization, Science
237: 67 (1987).PubMedCrossRefGoogle Scholar
G. S. Golumbeski Jr. and R. L. Dimond, The use of tolerization in the production of monoclonal antibodies against minor antigenic determinants, Anal. Biochem.
154: 373 (1986).PubMedCrossRefGoogle Scholar
S. K. Ou, C. McDonald, and P. H. Patterson, Comparison of two techniques for targeting the production of monoclonal antibodies against particular antigens, J. Immunological Methods
145: 111 (1991).CrossRefGoogle Scholar
R. Schwartz and W. Dameshek, Drug-induced immunological tolerance, Nature
183: 1682 (1959).PubMedCrossRefGoogle Scholar
W. D. Matthew and A. W. Sandrock Jr., Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies, J. Immunological Methods
100: 73 (1987).CrossRefGoogle Scholar
C. V. Williams, C. L. Stechmann, and S. C. McLoon, Subtractive immunization techniques for the production of monoclonal antibodies to rare antigens, Biotechniques
12: 842 (1992).PubMedGoogle Scholar
M. C. Berenbaum, Immunology. A screen for agents inhibiting the immune response and the growth of tumours, Nature
196: 384 (1962).PubMedCrossRefGoogle Scholar
R. Hanan and J. Oyama, Inhibition of antibody formation in mature rabbits by contact with the antigen at an early age, J. Immunol.
73: 49 (1954).PubMedGoogle Scholar
F. J. Dixon and P. H. Maurer, Immunologic unresponsiveness induced by protein antigens, J. Exp. Med.
101: 245 (1954).CrossRefGoogle Scholar
R. T. Smith and R. A. Bridges, Immunological unresponsiveness in rabbits produced by neonatal injection of defined antigens, J. Exp. Med.
108: 227 (1958).PubMedCrossRefGoogle Scholar
R. E. Billingham, L. Brent, and P. B. Medawar, “Actively acquired tolerance” of foreign cells, Nature
172: 603 (1953).PubMedCrossRefGoogle Scholar
© Springer Science+Business Media New York 1993